Hyaluronidase (Vitrase®) - ISTA

Drugs in R and D

Volumn 4, Issue 3, 2003, Pages 194-197

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIDASE; KERAFORM; KERATASE; UNCLASSIFIED DRUG; HYALURONOGLUCOSAMINIDASE; NEW DRUG;

ARTICLE; CATARACT; CLINICAL TRIAL; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; VITREOUS HEMORRHAGE; REVIEW;

CLINICAL TRIALS; DIABETIC RETINOPATHY; DRUGS, INVESTIGATIONAL; HUMANS; HYALURONOGLUCOSAMINIDASE; VITREOUS HEMORRHAGE;

EID: 0038302199     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304030-00010     Document Type: Article

References (6)

1. ISTA Pharmaceuticals Inc. ISTA Pharmaceuticals Announces FDA Acceptance of Vitrase NDA. Media Release: 17 Dec 2002. Available from URL: http://www.istavision.com
2. ISTA Pharmaceuticals Inc. ISTA Pharmaceuticals' Vitrase Reviewed by FDA Advisory Committee. Media Release: 17 Mar 2003. Available from URL: http://www.prnewswire.com
3. ISTA Pharmaceuticals Inc. ISTA Pharmaceuticals Receives FDA Approvable Letter for Vitrase. Media Release: 4 Apr 2003. Available from URL: http://www.istavision.com
4. Advanced Corneal Systems Inc. Advanced Corneal Systems presents final results from U.S. phase II trial of Vitrase. Media Release: [2 pages], 10 Nov 1998
5. Advanced Corneal Systems Inc. Phase III clinical trial results support ability of Vitrase to safely and effectively clear vitreous hemorrhage. Media Release: [2 pages], 25 Jun 1998
6. ISTA Pharmaceuticals Inc. ISTA Pharmaceuticals announces clinical trial results of vitrase for the treatment of diabetic retinopathy. Media Release: [3 pages], 7 Jan 2002. Available from URL: http://www.istavision.com